Contents Menu
resource typejournal article
resource type
Result 7501 Items
Id (<span class="translation_missing" title="translation missing: en.view.desc">Desc</span>)
Creators : Shiraishi Mami | Umeda Hirotsugu | Nonaka Ryo | Kawasaki Keisuke | Mishima Katsuaki Publishers : Yamaguchi University medical association Date Issued : 2024-02-29
Creators : Kamada Ayane | Fukuba Yui | Murakami Kyoko | Kutsunugi Saeko Publishers : Yamaguchi University medical association Date Issued : 2023-11-27
Creators : Isomura Yumi | Tsutsumi Masae Publishers : Yamaguchi University medical association Date Issued : 2023-11-27
Creators : Himemiya-Hakucho Ayako | Taketani Ayumi | Nakagawa Aoi | Sakai Hiroki | Ninomiya Risa | Shigemoto Azumi | Takase Izumi Publishers : Yamaguchi University medical association Date Issued : 2023-11-27
Creators : Kobayashi Shigeki Publishers : Yamaguchi University medical association Date Issued : 2023-11-27
Creators : Okada Seigo Publishers : Yamaguchi University medical association Date Issued : 2023-11-27
Creators : Oishi Toshiyuki | Kitase Akira | Tanaka Hiroko Publishers : Yamaguchi University medical association Date Issued : 2023-09-01
Creators : Hidaka Reina | Suehiro Yutaka | Kodama Masaki | Fukuda Masakazu | Kunimune Yuki | Okayama Naoko | Nakahara Yukiko | Nishioka Mitsuaki | Kobayashi Shigeki | Yano Masafumi | Yamasaki Takahiro Publishers : Yamaguchi University medical association Date Issued : 2023-09-01
Creators : Kiyonaga Asako | Nagata Chizuru Publishers : Yamaguchi University medical association Date Issued : 2023-09-01
Creators : Matsui Koki | Yamasaki Ayano | Suehiro Yutaka | Hoshida Tomomi | Saeki Issei | Yamauchi Yurika | Matsumoto Toshihiko | Higaki Shingo | Fujii Ikuei | Suzuki Chieko | Takami Taro | Sakaida Isao | Yamasaki Takahiro Publishers : Yamaguchi University medical association Date Issued : 2023-09-01
Creators : Nagai Hiroyuki | Takami Taro Publishers : Yamaguchi University medical association Date Issued : 2023-05-29
Creators : Ikeshita Takahiro | Kuga Takayuki | Shigeta Masatoshi | Yano Yuka Publishers : Yamaguchi University medical association Date Issued : 2023-05-29
Creators : Hisanaga Takuro | Takeuchi Yuriko | Nishimoto Arata | Katsura Shunsaku | Shirasawa Bungo Publishers : Yamaguchi University medical association Date Issued : 2023-05-29
Creators : Kaino Miyuki | Harima Yohei | Tsuyama Takanori | Nishi Maiko | Hitosugi Tomoki | Urata Yohei | Nakamura Yohei | Kaino Seiji Publishers : Yamaguchi University medical association Date Issued : 2023-02-28
Creators : Miyamoto Izumi | Yamase Hiroaki | Tado Asami Publishers : Yamaguchi University medical association Date Issued : 2023-02-28
Creators : Tsutsumi Masae | Suenaga Hiromi | Nagata Chizuru | Nogaki Horoshi | Kodama Etsuko | Isomura Yumi Publishers : Yamaguchi University medical association Date Issued : 2023-02-28
Creators : Kataoka Masami | Nogaki Horoshi | Hase Ryosuke Publishers : Yamaguchi University medical association Date Issued : 2023-02-28
A 88-year-old man who underwent abdominoperineal resection for rectal cancer 40 years earlier. The patient visited our hospital because of abdominal pain and vomiting. An abdominal CT scan showed an abdominal incisional hernia with a 23×15mm orifice in the midline of lower abdomen. The patient diagnosed with severe aortic valve stenosis on echocardiography. We performed elective surgery under intravenous anesthesia using ketamine and local anesthesia. The patient was discharged on postoperative day 8, and the postoperative course was uneventful. No recurrence has occurred 16 months after the operation. In conclusion, our strategy for patient with severe aortic valve stenosis is safe and effective.
Creators : Futatsugi Motonori Publishers : Yamaguchi University medical association Date Issued : 2022-12-01
Anaplastic large cell lymphoma(ALCL)is a rare peripheral T-cell lymphoma. According to anaplastic lymphoma kinase(ALK)expression, the World Health Organization classifies ALCL into two subtypes:ALK-positive or ALK-negative. Anthracycline-based combination chemotherapy is a standard frontline treatment for ALK-positive ALCL, with a long-term event- free survival rate of 60%-70%. For the salvage treatments of relapsed or refractory cases, the efficacies of brentuximab vedotin or ALK inhibitor have been established. We undertook a phase II clinical trial to investigate the efficacy and safety of alectinib, which is a second-generation ALK inhibitor, for relapsed or refractory ALK-positive ALCL. Ten patients were enrolled, and objective responses were documented in eight patients(80%),with six complete responses. Allogeneic hematopoietic stem cell transplantation(allo-HSCT)has also been reported to be one of curative treatments for relapsed or refractory ALCL. However, a high rate of treatment-related mortality was observed in allo-HSCT because of the myeloabrative conditioning regimen. We have reported the efficacy of the reduced-intensity conditioning(RIC)regimen for relapsed or refractory ALCL including the patients who did not obtain complete remission at allo-HSCT. The RIC regimen might be able to improve the outcomes of allo-HSCT by reducing treatment-related mortality.
Creators : Fukano Reiji Publishers : Yamaguchi University medical association Date Issued : 2022-12-01
A 69-year-old deaf-mute man received 6 cycles of R-CHOP therapy for diffuse large B-cell lymphoma(DLBCL)of the stomach. Although he showed a complete response to this therapeutic regimen, the patient developed intractable diarrhea upon completion of chemotherapy. He was diagnosed with cytomegalovirus(CMV)enteritis and was administered ganciclovir and foscarnet;however, CMV infection persisted. We suspected immunodeficiency other than that associated with chemotherapy-induced immunosuppression. Further examinations revealed a decrease in the CD4^+ T lymphocyte count and positive results on anti-human immunodeficiency virus(HIV)antibody testing, which confirmed HIV infection, and he was diagnosed with acquired immunodeficiency syndrome(AIDS).Antiviral therapy was initiated, and the HIV-RNA viral load became undetectable;however, the CD4^+ T lymphocyte count recovery was insufficient. Despite the clinical presentation of an AIDS-indicator disease, diagnosis of HIV infection was delayed, which may be attributable to deaf-mutism and the patient’s advanced age that may have led to bias among the medical staff and prevented prompt diagnosis of HIV infection.
Creators : Hamada Risako | Sakai Kohei | Konaka Kiminori | Nakayama Ayana | Nakano Kohei | Matsumura Takuro | Tominaga Takayuki | Fujioka Yuka | Takahashi Toru Publishers : Yamaguchi University medical association Date Issued : 2022-08-31
Related Journals
山口医学 Volume 9 Issue 5 54 山口医学 Volume 9 Issue 6 48 山口医学 Volume 9 Issue 4 47 山口医学 Volume 9 Issue 1 43 山口医学 Volume 9 Issue 3 42 山口医学 Volume 9 Issue 2 42 山口医学 Volume 11 Issue 2 35 山口医学 Volume 10 Issue 3 31 山口医学 Volume 6 Issue 4 29 山口医学 Volume 6 Issue 3 26 山口医学 Volume 10 Issue 4 26 山口医学 Volume 7 Issue 4 26 山口医学 Volume 10 Issue 2 23 山口医学 Volume 10 Issue 1 22 山口臨床医学 Volume 3 Issue 2-4 22 山口医学 Volume 7 Issue 5 21 The journal of Yamaguchi area studies Volume 14 21 Journal of East Asian studies Volume 18 21 山口医学 Volume 33 Issue 6 19 山口医学 Volume 7 Issue 3 19 The journal of Yamaguchi area studies Volume 9 19 Journal of East Asian studies Volume 13 19 Journal of East Asian studies Volume 14 19 山口医学 Volume 7 Issue 2 18 山口医学 Volume 31 Issue 6 18 山口医学 Volume 40 Issue 1 18 山口医学 Volume 6 Issue 2 17 山口医学 Volume 39 Issue 2 17 山口臨床医学 Volume 2 Issue 1 17 山口医学 Volume 33 Issue 4 16 山口医学 Volume 39 Issue 3 16 Journal of East Asian studies Volume 15 16 山口医学 Volume 5 Issue 2 15 山口医学 Volume 5 Issue 3 15 山口医学 Volume 5 Issue 1 15 山口医学 Volume 30 Issue 4 15 山口医学 Volume 29 Issue 4 15 アジアの歴史と文化 Volume 16 15 山口医学 Volume 29 Issue 3 15 山口医学 Volume 19 Issue 2-4 15 Journal of East Asian studies Volume 11 15 アジアの歴史と文化 Volume 18 15 山口医学 Volume 12 Issue 3 14 山口医学 Volume 20 Issue 2-4 14 山口医学 Volume 28 Issue 3-4 14 山口医学 Volume 39 Issue 1 14 山口医学 Volume 16 Issue 2 14 山口医学 Volume 18 Issue 3-4 14 Journal of East Asian studies Volume 16 14 山口医学 Volume 40 Issue 3 14
Show More
Show Less